SAM
KROS icon

Smartleaf Asset Management’s Keros Therapeutics KROS Stock Holding History

Smartleaf Asset Management’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.31K Hold
394
– – ﹤0.01% 2729
2026
Q1 		$4.21K Hold
394
– – ﹤0.01% 2735
2025
Q4 		$7.99K Buy
+394
New +$6.91K ﹤0.01% 2485
2024
Q4 		– Sell
-55
Closed -$3.1K – 2971
2024
Q3 		$3.1K Buy
+55
New +$2.72K ﹤0.01% 2326

Other funds holding KROS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Smartleaf Asset Management's KROS Position: Q2 2026 in Review

Smartleaf Asset Management held its Keros Therapeutics (KROS) position steady in Q2 2026 at 394 shares worth $4.31K. The position accounts for ﹤0.01% of the portfolio, ranked #2729.

Smartleaf Asset Management first reported a position in KROS in Q3 2024 and has held it in 4 quarters since. The position peaked at $7.99K in Q4 2025. 132 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

  • Smartleaf Asset Management held 394 shares of Keros Therapeutics worth $4.31K as of Q2 2026.
  • Smartleaf Asset Management left its Keros Therapeutics share count unchanged in Q2 2026.
  • Keros Therapeutics made up ﹤0.01% of Smartleaf Asset Management's portfolio in Q2 2026, its #2729 holding.
  • Smartleaf Asset Management first reported a position in Keros Therapeutics in Q3 2024 and has held it in 4 quarters since.
  • Smartleaf Asset Management's Keros Therapeutics position peaked at $7.99K in Q4 2025.
  • 132 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on Smartleaf Asset Management's 13F filing for Q2 2026, filed 12 Aug 2026.